Special Report: Biotech incubator taps investors through in-house brokerage

Last August, National Securities Corp analyst Jonathan Aschoff was bullish on Avenue Therapeutics Inc (ATXI.O), a fledgling biotechnology company with no revenue and one drug in clinical trials. In a research note posted on National’s website, he rated the newly listed stock a “buy” and predicted that the share price would more than double in a year.